Cargando…

The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM

The glucagon-like peptide-1 (GLP-1) is a peptide with incretin activity and plays an important role in glycemic control as well as the improvement of insulin resistance in type 2 diabetes mellitus (T2DM). However, the short half-life of the native GLP-1 in circulation poses difficulties for clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qing, Guo, Haixin, Mao, Wenwei, Qian, Xiuping, Liu, Yangang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143976/ https://www.ncbi.nlm.nih.gov/pubmed/37111687 http://dx.doi.org/10.3390/pharmaceutics15041202

Ejemplares similares

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice
por: Hedin, Karl Alex, et al.
Publicado: (2023)

Micro/Nanorobot: A Promising Targeted Drug Delivery System
por: Hu, Mengyi, et al.
Publicado: (2020)

Circadian secretion rhythm of GLP-1 and its influencing factors
por: Liu, Chuanfeng, et al.
Publicado: (2022)

ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients
por: Mohandas, Deene, et al.
Publicado: (2022)

GLP-1 receptor agonists modulate blood glucose levels in T2DM by affecting Faecalibacterium prausnitzii abundance in the intestine
por: Liang, Lei, et al.
Publicado: (2023)

The Effects of Oral Probiotics on Type 2 Diabetes Mellitus (T2DM): A Clinical Trial Systematic Literature Review
por: Paquette, Simon, et al.
Publicado: (2023)

GLP-1R Signaling and Functional Molecules in Incretin Therapy
por: Wan, Wenwei, et al.
Publicado: (2023)

Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats
por: Pegah, Atefeh, et al.
Publicado: (2021)

Memory improvement in senile rats after prebiotic and probiotic supplementation is not induced by GLP‐1
por: Servín‐Casas, Gabriela Andrea, et al.
Publicado: (2022)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Morphology, Structure and Function Characterization of PEI Modified Magnetic Nanoparticles Gene Delivery System
por: Zhao, Xiang, et al.
Publicado: (2014)

Oral GLP1 Analog: Where Does the Tide Go?
por: Gardner, Hannah, et al.
Publicado: (2020)

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
por: Pechenov, Sergei, et al.
Publicado: (2021)

Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery
por: Kweon, Seho, et al.
Publicado: (2023)

Engineered probiotics Clostridium butyricum‐pMTL007‐GLP‐1 improves blood pressure via producing GLP‐1 and modulating gut microbiota in spontaneous hypertension rat models
por: Wang, Xin‐liang, et al.
Publicado: (2022)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
por: Abdalqadir, Nyan, et al.
Publicado: (2022)

Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs
por: Pratap-Singh, Anubhav, et al.
Publicado: (2023)

HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity
por: Mohanan, P.P., et al.
Publicado: (2023)

THERAPEUTIC DELIVERY OF ANG(1-7) VIA GENETICALLY MODIFIED PROBIOTIC: A DOSING STUDY
por: Carter, Christy S
Publicado: (2019)

Therapeutic Delivery of Ang(1–7) via Genetically Modified Probiotic: A Dosing Study
por: Carter, Christy S, et al.
Publicado: (2020)

Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery
por: Ismail, Ruba, et al.
Publicado: (2019)

I-14 Molecular pathomechanism of DM2/PROMM: similarities and differences between DM1 and DM2
por: Meola, G.
Publicado: (2011)

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
por: Quarta, Carmelo, et al.
Publicado: (2022)

Enzymatic Crosslinked Hydrogels of Gelatin and Poly (Vinyl Alcohol) Loaded with Probiotic Bacteria as Oral Delivery System
por: Corona-Escalera, Aldo F., et al.
Publicado: (2022)

Oral Glucose Tolerance Testing identifies HIV+ infected women with Diabetes Mellitus (DM) not captured by standard DM definition
por: Seang, Sophie, et al.
Publicado: (2016)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair
por: Wang, Wei, et al.
Publicado: (2022)

Peptidome Analysis of Pancreatic Tissue Derived from T1DM Mice: Insights into the Pathogenesis and Clinical Treatments of T1DM
por: Zhang, Fan, et al.
Publicado: (2021)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Mucosal immunity–mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer’s patches
por: Lin, Sisi, et al.
Publicado: (2021)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

The physiological role of the brain GLP-1 system in stress
por: Holt, Marie K., et al.
Publicado: (2016)

Clinical and biochemical characteristics of familial type 1 diabetes mellitus (FT1DM) compared to non-familial type 1 DM (NFT1DM)
por: Alyafei, Fawzia, et al.
Publicado: (2018)

Application of Polysaccharide-Based Hydrogels as Probiotic Delivery Systems
por: Kwiecień, Iwona, et al.
Publicado: (2018)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment
por: Lohia, Sonnal, et al.
Publicado: (2023)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
por: Panfili, Eleonora, et al.
Publicado: (2023)

Analysis of patient medication compliance and quality of life of physician-pharmacist collaborative clinics for T2DM management in primary healthcare in China: A mixed-methods study
por: Xiao, Jie, et al.
Publicado: (2023)

Study on the Hyperglycemic Effect of GLP-1 in Spinibarbus denticulatus by Oral Administration and Intraperitoneal Injection Methods
por: Luo, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0deh2i8lf7f0h7to9ip32f5aav